The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: So Alex, would you just provide a brief overview of your Company and yourself for those less familiar with the story?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Great. So you're just starting at a high level. Would you walk through the traditional method of drug discovery and why has traditionally taken so
long?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: And so maybe just turning to your product portfolio. Can you walk us through your generative AI engine in creating antibodies and next-gen
biologics?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Got it. And then going after this, would you walk through the pieces of your integrated drug platform and how each operates?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Perfect. You also have a lot of exciting collaborations. Would you discuss your work with Merck and NVIDIA and how these should help grow your
business?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Yeah. So going after that, would you walk through your more recent announcements with Caltech and Google Ventures?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 26, 2023 / 12:10PM, ABSI.OQ - Absci Corp at Cantor Fitzgerald Global Healthcare Conference
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Great. And then maybe just -- can we spend some more time on your commercialization plan and how you go about these partnerships?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: And next, would you walk through how you view the competitive landscape and IP protection around your platform?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Perfect. Then just in terms of catalysts over the next 12, 24 months, which would you think you'd be [thinking] about?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Sounds great. Looking forward to it. And then lastly, can we just walk through your balance sheet and how you view your path to profitability?
Question: Ross Osborn - Cantor Fitzgerald LP - Analyst
: Great. Well, with that, I'd like to thank you for joining our Cantor conference today. Appreciate your time.
|